Novartis to invest $500 million in new Singapore site
ZURICH (Reuters) - Swiss drugmaker Novartis said on Wednesday it would spend more than $500 million on a new biotechnology production site in Singapore to support its growing pipeline of biologics.
The Basel-based company said construction of the new site would begin in early 2013 and the facility is expected to be fully operational by the end of 2016.
Novartis said the site will focus on drug substance manufacturing based on cell culture technology.
(Reporting by Caroline Copley)
SYDNEY - Asian shares touched fresh three-year highs on Tuesday as investors in the region drew encouragement from a rally in Chinese markets, though caution was warranted given the torrent of U.S. economic news still to come this week.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.